Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06IAQ
|
|||
Former ID |
DAP000893
|
|||
Drug Name |
Ambenonium
|
|||
Synonyms |
Ambenonum; Ambenonium Base; Ambenonium kation; Mytelase (TN); (2-chlorophenyl)methyl-[2-[[2-[2-[(2-chlorophenyl)methyl-diethylazaniumyl]ethylamino]-2-oxoacetyl]amino]ethyl]-diethylazanium; 2,2'-[(1,2-dioxoethane-1,2-diyl)diimino]bis[n-(2-chlorobenzyl)-n,n-diethylethanaminium]
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Myasthenia gravis [ICD-11: 8C6Y; ICD-10: G70.0; ICD-9: 358] | Approved | [1] | |
Therapeutic Class |
Antiarrhythmic Agents
|
|||
Company |
Sanofi Aventis Us Llc
|
|||
Structure |
Download2D MOL |
|||
Formula |
C28H42Cl2N4O2+2
|
|||
Canonical SMILES |
CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2Cl
|
|||
InChI |
1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2
|
|||
InChIKey |
OMHBPUNFVFNHJK-UHFFFAOYSA-P
|
|||
CAS Number |
CAS 7648-98-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
9975, 5106491, 5792527, 8151446, 11113478, 26756578, 29221310, 46508143, 57321160, 76506773, 103107679, 103624065, 104111496, 104222117, 104299694, 117397200, 117465261, 124886912, 126407287, 134338170, 135027862, 136035395, 137005305, 160964456, 162656397, 175265408, 179225494, 196372339, 226628643, 241145075
|
|||
ChEBI ID |
CHEBI:2627
|
|||
SuperDrug ATC ID |
N07AA30
|
|||
SuperDrug CAS ID |
cas=007648988
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Acetylcholinesterase (AChE) | Target Info | Inhibitor | [2] |
KEGG Pathway | Glycerophospholipid metabolism | |||
Cholinergic synapse | ||||
Panther Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||
Muscarinic acetylcholine receptor 2 and 4 signaling pathway | ||||
Nicotinic acetylcholine receptor signaling pathway | ||||
Pathwhiz Pathway | Phospholipid Biosynthesis | |||
Pathway Interaction Database | ATF-2 transcription factor network | |||
WikiPathways | Monoamine Transport | |||
Biogenic Amine Synthesis | ||||
Acetylcholine Synthesis | ||||
Integrated Pancreatic Cancer Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010155. | |||
REF 2 | Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.